Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joël Rousseau

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Cells|January 11, 2024
Successful Correction by Prime Editing of a Mutation in the <i>RYR1</i> Gene Responsible for a MyopathyKelly Godbout, Joël Rousseau, Jacques P Tremblay
Molecular Therapy. Nucleic Acids|March 23, 2017
Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160Arnaud Perrin, Joël Rousseau, Jacques P Tremblay
General and Comparative Endocrinology|May 29, 2002
Modulation of prolactin expression by xenoestrogensJoël Rousseau, Louis Cossette, Sonya Grenier, et al.
Plos One|December 28, 2020
The protective mutation A673T in amyloid precursor protein gene decreases Aβ peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cellsAntoine Guyon, Joël Rousseau, Gabriel Lamothe, et al.
The CRISPR Journal|February 8, 2022
Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's DiseaseGuillaume Tremblay, Joël Rousseau, Cedric Happi Mbakam, et al.
Cells|May 13, 2026
Successful In Vitro Modification of the <i>Dmd</i> Gene Using Prime EditingAyesha Siddika, Fatima El Husseiny, Joël Rousseau, et al.
International Journal of Molecular Sciences|June 10, 2022
Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular DystrophyCédric Happi Mbakam, Joël Rousseau, Guillaume Tremblay, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 23, 2004
Novel Duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerismGeoffrey Camirand, Joël Rousseau, Marie-Eve Ducharme, et al.
Cells|May 27, 2026
Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical TranslationAyesha Siddika, Joël Rousseau, Félix Veillette, et al.
Molecular Therapy. Nucleic Acids|September 10, 2018
Increased Frataxin Expression Induced in Friedreich Ataxia Cells by Platinum TALE-VP64s or Platinum TALE-SunTagKhadija Cherif, Catherine Gérard, Joël Rousseau, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cells|January 11, 2024
Successful Correction by Prime Editing of a Mutation in the <i>RYR1</i> Gene Responsible for a MyopathyKelly Godbout, Joël Rousseau, Jacques P Tremblay
Molecular Therapy. Nucleic Acids|March 23, 2017
Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160Arnaud Perrin, Joël Rousseau, Jacques P Tremblay
General and Comparative Endocrinology|May 29, 2002
Modulation of prolactin expression by xenoestrogensJoël Rousseau, Louis Cossette, Sonya Grenier, et al.
Plos One|December 28, 2020
The protective mutation A673T in amyloid precursor protein gene decreases Aβ peptides production for 14 forms of Familial Alzheimer's Disease in SH-SY5Y cellsAntoine Guyon, Joël Rousseau, Gabriel Lamothe, et al.
The CRISPR Journal|February 8, 2022
Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's DiseaseGuillaume Tremblay, Joël Rousseau, Cedric Happi Mbakam, et al.
Cells|May 13, 2026
Successful In Vitro Modification of the <i>Dmd</i> Gene Using Prime EditingAyesha Siddika, Fatima El Husseiny, Joël Rousseau, et al.
International Journal of Molecular Sciences|June 10, 2022
Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular DystrophyCédric Happi Mbakam, Joël Rousseau, Guillaume Tremblay, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 23, 2004
Novel Duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerismGeoffrey Camirand, Joël Rousseau, Marie-Eve Ducharme, et al.
Cells|May 27, 2026
Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical TranslationAyesha Siddika, Joël Rousseau, Félix Veillette, et al.
Molecular Therapy. Nucleic Acids|September 10, 2018
Increased Frataxin Expression Induced in Friedreich Ataxia Cells by Platinum TALE-VP64s or Platinum TALE-SunTagKhadija Cherif, Catherine Gérard, Joël Rousseau, et al.
Pageof 3